Core Insights - The company reported total net revenue of $13.9 million and a net income of $2.0 million, equating to $0.21 net income per share basic [1] - Adjusted EBITDA was $(0.6) million, which includes investments related to the launch of EXXUA [1] - The company has a cash balance of $32.6 million as of September 30, 2025 [1] - The launch of EXXUA (gepirone) extended-release tablets is on track for the fourth calendar quarter of 2025, targeting the over $22 billion U.S. prescription major depressive disorder market [1] - A conference call and webcast is scheduled for November 13, 2025, at 4:30 p.m. Eastern time [1]